NCT07217106Completed
A Study of Accelerated Guideline-Directed Medical Therapy for Heart Failure
A Retrospective Assessment of Accelerated Guideline-Directed Medical Therapy for Heart Failure
Source: ClinicalTrials.gov · Last updated 15 Oct 2025
Brief summary (registry, in English)
The aim of the study was to evaluate the efficacy and safety of a Guideline-Directed Medical Therapy (GDMT) clinic within a general cardiology practice relative to usual care. This study analyzed data from patients with heart failure (HF) who were referred to the GDMT clinic at Massachusetts General Hospital (MGH). For the comparator arm, patients in the GDMT clinic were matched to data of patients contained within in the MGH Research Patient Data Repository (RPDR).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 342 (actual)
- First submitted
- 13 Oct 2025
- Start date
- 3 Mar 2024
- Primary completion date
- 1 Jul 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Heart failure
- NCT number
- NCT07217106
What you commit to
- Study type: Observational
- Participants enrolled: 342
- From 3 Mar 2024 to the primary completion date, 1 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Advanced HF
- Inotropic support
- Transplant or mechanical circulatory support (MCS) planned
- Enrolled in hospice or palliative care
Other illness
- Untreated severe valvular heart disease
- Life expectancy \<12 months due to non-cardiovascular (CV) disease
Lab values
- End-stage kidney disease
- o glomerular filtration rate (GFR) \<15 mL/min/1.73m\^2 or on renal replacement therapy
Other
- Planned referral to the Advanced HF program
- Decompensated HF
- Pericardial constriction
- Hypertrophic cardiomyopathy
- Unwillingness or inability to take GDMT
- Pregnancy or breast feeding
Who the study is looking for
- Diagnosis of HF, including new onset disease
- Established cardiovascular follow up at the hospital
- Received sub-optimal medical care defined as \<50% target doses of GDMT agents
- Left ventricular ejection fraction (LVEF) \<50%
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Coordinator of this site? Confirm its status | East Hanover | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.